BioCentury
ARTICLE | Clinical News

ALTU-238: Phase II started

May 18, 2009 7:00 AM UTC

Altus disclosed that in March it began an open-label, active-controlled, U.S. Phase II trial (0001194) to compare 0.3, 0.6 or 0.9 mg/kg of subcutaneous ALTU-238 given weekly vs. 0.043 mg/kg Nutropin ...